EGFR and lung adenocarcinoma: Mok et al. compared head-to-head gefitinib versus carboplatin-paclitaxel in patients with untreated lung adenocarcinoma, non-smokers or ex-smokers, demonstrating an increase in progression-free survival (PFS) in patients treated with gefitinib, with the greater benefit in the subgroup of patients who were positive for EGFR mutation [35].